A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects With Relapsed Chronic Lymphocytic Leukemia.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms COMPLEMENT 2
- Sponsors GlaxoSmithKline; Novartis
- 30 Nov 2017 This trial has been completed in Greece (End date: 2017-10-25).
- 23 Nov 2017 This trial has been completed in Bulgaria (End Date:2017-10-25).
- 25 Jun 2017 Results of assessment of clinical associations of gene mutations in this trial presented at the 22nd Congress of the European Haematology Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History